Low-dose exogenous melatonin plus evening dim light and time in bed scheduling advances circadian phase irrespective...

Area of Science:

• Chronobiology
• Sleep Medicine
• Pharmacology

Background:

• Delayed sleep-wake phase disorder (DSWPD) is a circadian rhythm disorder characterized by a persistent pattern of sleep onset and wake times later than desired.
• Current treatment strategies for DSWPD often involve melatonin supplementation and behavioral interventions, but the optimal timing for melatonin administration remains a subject of investigation.
• Accurate determination of the dim light melatonin onset (DLMO) is crucial for chronotherapy, but its measurement can be complex.

Purpose of the Study:

• To preliminarily evaluate the efficacy of low-dose melatonin treatment combined with behavioral interventions for DSWPD.
• To determine if knowing the precise dim light melatonin onset (DLMO) time is advantageous compared to estimating it for treatment timing.
• To assess the impact of melatonin administration timing relative to DLMO on circadian and sleep parameters in DSWPD patients.

Main Methods:

• A randomized, controlled, double-blind trial involving 40 adults diagnosed with DSWPD.
• Participants received 0.5 mg of melatonin for 4 weeks, administered either 3 hours before measured DLMO or 5 hours before estimated sleep-onset time (based on actigraphy).
• Both groups received concurrent behavioral interventions including evening dim light exposure and time in bed scheduling. Primary outcome was change in DLMO, with secondary outcomes including various sleep parameters and quality of life measures.

Main Results:

• Significant improvements were observed in most circadian and sleep parameters across both groups after treatment.
• No statistically significant group-by-visit interactions were found, indicating similar treatment effects regardless of whether melatonin was timed to measured or estimated DLMO.
• While not statistically significant after Bonferroni correction, trends suggested potential benefits in certain sleep parameters and quality of life measures.

Conclusions:

• Low-dose melatonin administered with behavioral interventions appears effective in improving circadian and sleep parameters for DSWPD.
• The precise timing of melatonin administration, whether based on measured or estimated DLMO, did not significantly alter treatment outcomes in this preliminary study.
• Larger-scale trials are warranted to confirm these findings and further elucidate the role of DLMO timing in DSWPD chronotherapy.